@article{NeumaierWeissVeldemanetal.2021,
  author    = {Neumaier, Felix and Weiss, Miriam and Veldeman, Michael and Kotliar, Konstantin and Wiesmann, Martin and Schulze-Steinen, Henna and H{\"o}llig, Anke and Clusmann, Hans and Schubert, Gerrit Alexander and Albanna, Walid},
  title     = {Changes in endogenous daytime melatonin levels after aneurysmal subarachnoid hemorrhage - preliminary findings from an observational cohort study},
  series = {Clinical Neurology and Neurosurgery},
  volume    = {208},
  journal   = {Clinical Neurology and Neurosurgery},
  number    = {Article No.: 106870},
  publisher = {Elsevier},
  address   = {Amsterdam},
  issn      = {0303-8467},
  doi       = {10.1016/j.clineuro.2021.106870},
  year      = {2021},
  abstract  = {Aneurysmal subarachnoid hemorrhage (aSAH) is associated with early and delayed brain injury due to several underlying and interrelated processes, which include inflammation, oxidative stress, endothelial, and neuronal apoptosis. Treatment with melatonin, a cytoprotective neurohormone with anti-inflammatory, anti-oxidant and anti-apoptotic effects, has been shown to attenuate early brain injury (EBI) and to prevent delayed cerebral vasospasm in experimental aSAH models. Less is known about the role of endogenous melatonin for aSAH outcome and how its production is altered by the pathophysiological cascades initiated during EBI. In the present observational study, we analyzed changes in melatonin levels during the first three weeks after aSAH.},
  language  = {en}
}